A Study to Evaluate the Efficacy, Safety and Tolerability of Triple Therapy with Peginterferon Plus Ribavirin Plus either Telaprevir or Boceprevir in Chronic Hepatitis C Virus (HCV) Infected Patients with Minimal versus Advanced Fibrosis

Trial Profile

A Study to Evaluate the Efficacy, Safety and Tolerability of Triple Therapy with Peginterferon Plus Ribavirin Plus either Telaprevir or Boceprevir in Chronic Hepatitis C Virus (HCV) Infected Patients with Minimal versus Advanced Fibrosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Dec 2015

At a glance

  • Drugs Boceprevir (Primary) ; Peginterferon (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top